FiercePharmaOriginal article
{"a":[{"_":"As FDA makes Lipfendra poster child of CNPV pilot, Merck charts long-term path for first PCSK9 pill","$":{"href":"/pharma/fda-makes-lipfendra-poster-child-cnpv-pilot-merck-charts-long-term-path-first-pcsk9-pill","hreflang":"en"}}]}
RegulatoryLipfendraPositive
AI Analysis
Summary
Merck's Lipfendra, the first oral PCSK9 inhibitor, has been selected by the FDA as the flagship program for its CNPV pilot program. The company aims to overcome the historical disappointment of the PCSK9 drug class by leveraging regulatory support and physician adoption.
Outcome Details
Lipfendra selected as poster child for FDA's CNPV (Complex Novel Product Verification) pilot program
Importance:6/10
Sentiment:
0.60
PCSK9oral_formulationFDA_pilotcholesterolfirst-in-class
Related Companies
Read the original article
Published by FiercePharma on August 4, 2026 2:39 PM